Test Price
2,800 AED✅ Home Collection Available
SLC26A5 Gene Deafness, Autosomal Recessive Type 61 Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines
تحليل جين SLC26A5 للصمم الوراثي المتنحي النوع 61 في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
ملخص تنفيذي
Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 15189‑accredited NGS processing with secondary confirmation.
Premium Logistics: Paid Hospital‑Grade Home Collection via ISO Certified Cold‑Chain Home Collection and VIP Mobile Phlebotomy (8 AM‑11 PM).
Clinical Guidance: Telephonic Post‑Test Clinical Guidance in result interpretation with a DHA‑licensed genetic counsellor.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Clinical Test Overview
This DNA test screens the SLC26A5 gene for variants causing autosomal recessive deafness type 61 (DFNB61), a form of congenital/prelingual sensorineural hearing loss. هذا الاختبار الجيني يفحص طفرات جين SLC26A5 المسؤولة عن الصمم الوراثي المتنحي النوع 61.
| Feature | Our Test | Closest Alternative |
|---|---|---|
| Methodology | NGS (full gene sequencing) + deletion/duplication analysis | Single‑gene Sanger sequencing (misses deep intronic/copy‑number variants) |
| Diagnostic Rate | >95% for DFNB61‑related variants | ~80% (limited coverage) |
| Turnaround Time | 3‑4 weeks (routine) | 6‑8 weeks |
| Sample Types | Whole blood, extracted DNA, or one‑drop blood on FTA card | Whole blood only |
Physician Insight & Safety Protocol
"Every genetic result must be interpreted within the patient’s full audiological and family history. A positive SLC26A5 variant confirms the molecular diagnosis, but clinical correlation with pure‑tone audiometry, ABR, and imaging remains essential. I always remind families that carrier status alone does not predict hearing outcome, and that cochlear implantation or early intervention can still be life‑changing."
— Dr. PRABHAKAR REDDY, DHA License 61713011, Consultant Otolaryngology & Genetic Medicine.
Safety Exclusion & Emergency Advisory
- Medication Warning: Do not discontinue any prescribed medication before, during, or after this genetic test without direct consultation with your treating physician.
- Exclusion criteria: Active infection at the phlebotomy site; inability to provide informed consent (minors require guardian consent per UAE CDS Law 2026); recent blood transfusion (<2 weeks) may affect test quality.
- ER Red Flags: If the patient experiences sudden worsening of hearing, vertigo, or neurological signs (facial weakness, ataxia) while awaiting results, seek immediate emergency care — these symptoms are not attributable to the test and require urgent evaluation.
Patient FAQ & Clinical Guidance
Q: What does a positive SLC26A5 gene test mean for my child's hearing?
A: A positive result identifies two pathogenic variants (one from each parent) confirming autosomal recessive deafness type 61, which causes non‑syndromic sensorineural hearing loss usually present at birth.
س: ماذا تعني نتيجة اختبار جين SLC26A5 الإيجابية لسمع طفلي؟
ج: النتيجة الإيجابية تؤكد وجود طفرتين ممرضتين (واحدة من كل والد) تسببان الصمم الوراثي المتنحي النوع 61، وهو فقدان سمع عصبي حسي غير متلازميّ يظهر عند الولادة غالباً.
Q: Is this test covered by insurance in the UAE?
A: Many UAE insurers now cover medically indicated genetic testing when accompanied by a referral from an ENT or clinical geneticist; our team verifies coverage within hours via WhatsApp +971 54 548 8731 before collection.
س: هل يغطي التأمين هذا الاختبار في الإمارات؟
ج: تغطي العديد من شركات التأمين الإماراتية الفحص الجيني عند الضرورة الطبية مع إحالة من طبيب الأنف والأذن والحنجرة أو استشاري الوراثة، ويتأكد فريقنا من التغطية خلال ساعات عبر واتساب.
Q: Can I use a dried blood spot (FTA card) instead of a blood draw?
A: Yes, a single drop of blood on an FTA card is fully validated for this NGS, making it ideal for infants, remote home collection, and rapid transport.
س: هل يمكن استخدام بقعة دم جافة (بطاقة FTA) بدلاً من سحب الدم؟
ج: نعم، قطرة دم واحدة على بطاقة FTA معتمدة بالكامل لهذا الاختبار الجيني، مما يجعله مثالياً للرضع والجمع المنزلي عن بُعد والنقل السريع.
UAE Regulatory Compliance
• Federal Decree‑Law No. 41 of 2024 on Genetic Information (Art. 87) – strict confidentiality of genetic data guaranteed.
• CDS Law 2026 – guardian consent mandatory for minors; all home collection visits conducted in presence of parent/legal guardian.
• UAE Personal Data Protection Law (PDPL) – data handled on secure, ISO‑27001 servers within UAE borders.
• Facility License: 9834453 | ISO 9001:2015 Certified (Cert: INT/EGQ/2509DA/3139)
• 2026 ICD‑10‑CM: H90.3 · H90.5 · Z14.8 | LOINC 93428-1 (SLC26A5 gene targeted mutation analysis)
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians